The KRAS and BRAF V600E mutation rates detected in our series by both Sanger sequencing and ASLNAqPCR are compatible with the data reported in the literature for colon adenocarcinoma (Table 6) and the other tumors analyzed [3], [4], [5], [11], [16], [27]. This evidence concerns the gene BRAF and colon adenocarcinoma.